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Response to the FDA Draft Guidance for Industry document:  
Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims (Docket 2006D-0044) 
 
Jakob B Bjorner, MD, PhD, Barbara Gandek, MS, Jason Cole, PhD, Mark Kosinski, MA, 
Gene Wallenstein, PhD, Milena Anatchkova, PhD, John E. Ware Jr., PhD 
 
QualityMetric Inc. and Health Assessment Lab 
 
We would like to express our appreciation to the FDA for this well-written document, 
which presents a strong and cohesive argument for the use of PRO tools in clinical 
research as well as useful guidance on the sound application of PRO assessment in 
clinical trials.  
 
QualityMetric and Health Assessment Lab strongly support the overall goal of the 
Guidance to ensure that drug claims pertaining to PRO are backed up by sound 
measurement and research design. Since the draft guidance is likely to elicit numerous 
responses from the various stakeholders in PRO research, we would like to initially point 
out the places where we particularly strongly support the principles in the current version 
of the guidance. We will then provide some specific suggestions for modifications to 
various parts of the guidance and finally discuss a number of issues in more general 
terms. We are particularly enthusiastic about the following parts of the guidance: 
 
III.A. Why Use Patient-Reported Outcome Instruments in Medical Product Development? 
(Lines 92-137).  
This section presents a very well written description of the potential benefits of PRO 
assessment. We think this section is ideal as it is now. 
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Figure 1: The PRO Instrument Development and Modification Process and lines 183-
192.  
The wheel and spokes diagram presents a very nice framework for understanding PRO 
instrument development. 
 
A. Development of the Conceptual Framework and Identification of the Intended 
Application (lines 194-210, 249-279, 460-467).  
We agree with and support the recommendation to specify a conceptual framework and 
identify the concepts and domains to be measured based on this conceptual framework. 
The notion that the conceptual framework should be related to the claim sought is 
important and we would suggest that this aspect be given even more weight in the 
guidance – in line with the presentations at the Mayo Clinic meeting. We have some 
suggestions for improvement of the sections on single items and multi-domain 
instruments (lines 212-237, please see below), but we strongly support the intention of 
the FDA to evaluate the conceptual model by evaluating the relationships between 
individual items, domains, and the general concepts (lines 249-256), and to evaluate the 
intended application and populations for the PRO instrument. 
 
Section C, 4a. Defining a minimum important difference (lines 537-568).  
We enthusiastically support the distinction between minimal important difference (MID) 
as a benchmark for interpreting mean differences and the definition of a responder as 
pertaining to a change in an individual. We do not agree that an MID is usually specific 
to the population under study (please see below), but we agree that the use of a variety of 
methods to determining MID is generally helpful. 
 
Specific suggestions for modifications to the guidance: 
Line 153-156 
"Some PRO instruments (e.g., health-related quality of life instruments) attempt to 
measure both the effectiveness and the side effects of treatment. PRO instruments that are 
used in clinical trials to support effectiveness claims should measure the adverse 
consequences of treatment separately from the effectiveness of treatment." 
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Suggested revision: 
"Some PRO instruments (e.g., health-related quality of life instruments) attempt to 
measure both the effectiveness and the side effects of treatment. Clinical trials to support 
effectiveness claims should be designed to assess the adverse consequences of treatment 
separately from the effectiveness of treatment." 
 
Motivation: 
Separation of side effects from treatment effects is an important topic that extends 
beyond a particular PRO instrument. Steps to separate these effects should be taken in 
various parts of the study design (e.g., frequency of assessment of side effects, efficient 
reporting mechanism). Further, the original sentence could be misunderstood to mean 
that the separation of effectiveness from side effects could only be achieved by a PRO 
instrument measuring these separately and not by combining an instrument aimed at 
evaluating effectiveness with an instrument aimed at evaluating side effects. 
 
Line 178-181 
“When considering an instrument that has been modified from the original, the FDA 
generally plans to evaluate the modified instrument just as it would a new one. Therefore, 
in such instances, we encourage sponsors to document the original development 
processes, all modifications made, and updated assessments of its measurement 
properties.”  
 
Suggested revision: 
“When considering an instrument that has been modified from the original, the 
requirements for documentation will depend on the extent and nature of the modification 
and the level of documentation of the original instrument. Therefore, in such instances, 
we encourage sponsors to document the original development processes, all 
modifications made, and updated assessments of its measurement properties.”  
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Motivation: 
The original statement appears to contradict section D line 582-583: The extent of 
additional validation recommended depends on the type of modification made.  The 
extensive definition of modification in section D also renders excessive the plan to 
evaluate modified instruments just as new ones. 
 
Line 214-223 
"If the concept of interest is general (e.g., physical function), a single-item PRO 
instrument is usually unable to provide a complete understanding of the treatment’s effect 
because a single item cannot capture all the domains of the general concept. 
For this reason, single-item questions about general concepts that imply multiple 
domains rarely provide sufficient evidence to support claims about that general concept. 
However, single-item questions about general concepts can be useful to help interpret 
multi-item measures of the same concept and to determine whether important items or 
domains of a general concept are missing (e.g., when results using single general 
questions do not correlate with results using a multi-item questionnaire, this may be 
evidence that the questionnaire is not capturing all the important domains of the concept 
contained in the claim)." 
 
Suggested revision: 
"If the concept of interest is general (e.g., physical function), a single-item PRO 
instrument is usually unable to provide a complete understanding of the treatment’s effect 
because a single item cannot capture all the domains of the general concept. 
For this reason, single-item questions about general concepts that imply multiple 
domains rarely provide sufficient evidence to support claims about that general concept. 
However, single-item questions about general concepts can be valid measures of the 
patient’s own overall assessment of the concept. Thus, care should be taken in the 
labeling of the concept." 
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Motivation: 
The original text could be confusing: if a single-item measure does not capture all 
domains of a concept, it is hard to understand why a low correlation with results from a 
multi-item questionnaire should be taken as evidence that the questionnaire is not 
capturing all domains. The part of the multi-item questionnaire that shows low 
correlation with the single item could be the very part that is relevant but not captured by 
the single item. On the other hand, global single items can be valid measures of the 
patient’s global assessment of a health domain. One example of this is the strong body of 
evidence supporting the validity of single items on general health perception (see e.g. 1;2) 
 
Line 275-278 
"The FDA plans to compare the patient population used in the PRO instrument 
development process to the study populations enrolled in clinical trials to determine 
whether the instrument is appropriate to that population with respect to patient age, sex, 
ethnic identity, and cognitive ability." 
 
Suggested revision: 
"The FDA plans to compare the patient population used in the PRO instrument 
development process to the study populations enrolled in clinical trials to determine 
whether the instrument is appropriate to that population with respect to pertinent 
demographic variables, such as patient age, sex, ethnic/racial identity, and cognitive 
ability.  Pertinent demographic variables are those which have been empirically 
demonstrated to impact the construct measurement by the PRO. " 
 
Motivation: 
The largest change is to the inclusion of pertinent demographic variables, rather than a 
list of demographic variables.  Certain demographic variables may be pertinent to the 
measurement of the construct which are not included in the current list.  Moreover, 
certain constructs may have much literature which demonstrates no differences between 
demographic subgroups.  For example, crystallized IQ would likely not require additional 
revalidation on samples of 70 year old patients when it was validated on a group of 50 
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year old patients, as the measurement properties between these two groups are quite 
consistent between the groups.  This change to the language fits in well with the current 
language proposed on lines 525 through 530.   
 
Second, we have added in the term “racial”, as many demographers have now 
distinguished racial and ethnic identity as two different considerations (including the U.S. 
Census Bureau). 
 
Line 288-300, in particular 295 
"PRO instrument item generation is incomplete without patient involvement." 
 
Suggested revision: 
Item generation includes establishing the content to be covered by the items, generating 
item wording, evaluating the completeness of item coverage, performing initial 
assessment of clarity and readability. PRO instrument item generation is incomplete 
without patient involvement.  
 
Motivation: 
A clear definition of the term item generation would be helpful in clarifying this section 
and such a definition should also be put in the glossary. The text above is an attempt to 
provide such a definition. The original text could be interpreted to mean that patients 
should generate the item wording. However, if item wording comes directly from patient 
statements, considerable editing is often necessary to make the wording clear and 
unambiguous in a questionnaire context. Thus, patient involvement in evaluating 
completeness of content coverage and item clarity and readability should be sufficient.  
 
Line 298-300 
“The FDA plans to review instrument development (e.g., results from patient interviews 
or focus groups) to determine whether adequate numbers of patients have supported the 
opinion that the specific items in the instrument are adequate and appropriate to measure 
the concept.”  
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Suggested change: 
“The FDA plans to review instrument development (e.g., results from patient interviews 
or focus groups) to determine whether the items cover all aspects of the concept 
identified by patients, that item content is acceptable and understandable to patients, and 
that enough patients have been included to make the results generalizable to the 
populations in question.” 
 
Motivation: 
The original text could be misinterpreted to suggest that adequacy and appropriateness of 
items is supported if enough patients support the opinion that the specific items in the 
instrument are adequate and appropriate. This is a too simplistic description of the 
approach to evaluate content validity.  
 
Line 302-308 
"Items that ask patients to respond hypothetically or that give patients the opportunity to 
respond on the basis of their desired condition rather than on their actual condition are 
not recommended. For example, in assessing the concept performance of daily activities, 
it is more appropriate to ask whether or not the respondent performs specific activities 
(and if so, with how much difficulty) than whether or not he or she can perform daily 
activities (because patients may report they are able to perform a task even when they 
never do so). Of course, it would be critical to know that each item refers to something 
that patients actually do." 
 
Suggested revision: 
“Items should be appropriately selected to accurately assess the desired domain, which 
could be ‘physical function/disability’, ’pain’, ‘fatigue’, ‘emotional distress’, or others.   
Time frames, response categories, and context should be appropriate for the particular 
domain. Patient evaluations may be validated against external observation, e.g., actual 
observed ability to perform a described activity.  Such external validation provides a 
strong test of the measurement instrument and is recommended, when feasible.  Use of 
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items which are developed from very well-validated ‘legacy’ instruments or the 
instruments themselves is encouraged, especially when the FDA has a substantial 
experience with these instruments and items.” 
 
Motivation: 
The original wording seem to recommend against standard practice for many PRO 
domains such as physical functioning and general health perceptions, where people are 
being asked to assess their abilities or their health. However, there is substantial evidence 
to support the validity of such approaches. To name one example, standard scales for 
both physical functioning and general health perception are strong predictors of 
subsequent mortality – a relationship that would be unlikely, if the patients’ responses 
were strongly biased by a tendency to report “on the basis of their desired condition 
rather than on their actual condition”. For “performance of daily activities” (we assume 
that this refers to the concept also called physical functioning) the advice of the guidance 
is to: 1) ask whether the patient performs the specific activity, and 2) then ask about the 
difficulty of performing this activity. The problem with this approach is that if a patient 
does not perform a particular activity, we have no way of knowing whether he or she is 
incapable of doing this activity or whether he or she just has chosen not to do it within the 
chosen recall period. This would create a tremendous problem of scoring the data that 
would need to be solved either by sophisticated techniques to tailor the items and the 
scoring to each patient or by restricting the items to activities that would be performed by 
everyone, if they were capable of it. This latter solution would create severe ceiling 
problems that would substantially reduce the usefulness of the instrument. By seeking to 
improve something that does not seem to be a problem in practice, the guidance would in 
this particular case introduce more measurement problems than it would solve.  
 
Line 339-343 
“PRO instruments that require patients to rely on memory, especially if they must recall 
over a period of time, or to average their response over a period of time may threaten the 
accuracy of the PRO data. It is usually better to construct items that ask patients to 
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describe their current state than to ask them to compare their current state with an 
earlier period or to attempt to average their experiences over a period of time.” 
 
Suggested change 
“For PRO instruments that require patients to rely on memory, care must be taken to 
select an appropriate recall period. Long recall periods for everyday symptoms may 
threaten the accuracy of the PRO data. It is usually better to construct items that ask 
patients to describe their current state than ask them to compare their current state with 
an earlier period.” 
 
Motivation 
The implicit assumption in the original text that cognitive processing will hamper validity 
and accuracy ignores the fact that any response process relies on cognitive processing and 
to some extent on memory. Even if the item refers to the “current state”, patients have to 
define the time period which is referred to, and those definitions will vary. The original 
wording is too general; it does not clarify the term “period of time”, and can be read as a 
general recommendation of diaries over other standard PRO questionnaires. Both 
approaches have well described advantages and disadvantages.  
 
Line 367-369 
“Response options do not bias the direction of responses (e.g., offering one negative 
choice, one neutral choice, and two or more positive choices on a scale makes it more 
likely for patients to respond that they feel or function better). “ 
 
Suggested change: 
“Response options do not bias the direction of responses (in a post-intervention 
evaluation e.g., offering one negative choice, one neutral choice, and two or more 
positive choices on a scale makes it more likely for patients to respond that they feel or 
function better). “ 
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Motivation: 
Not all response scales can be bidirectional and balanced (e.g., pain rating scales). In a 
design with baseline and follow-up assessment, the issue of balanced response options is 
not a problem since real outcome is the difference between baseline and follow-up. Thus, 
the issue of balanced response scales is only relevant in designs that rely solely on post-
intervention assessment.  
 
Line 397-398 
“Format refers to the exact appearance of the instrument.” 
 
Suggested revision: 
“Format refers to the exact appearance of the questionnaire (or survey).” 
 
Motivation: 
Because the Glossary defines an “instrument” as being a means to capture data plus 
information that supports its use (e.g., documentation on scoring, analysis and 
interpretation of results), the word “instrument” may be too broad here, since materials 
such as user manuals and scoring documents generally are not seen by patients .  Thus, 
the word “questionnaire” might be substituted.  However, “questionnaire” as defined in 
the Glossary is limited to questions “shown to a respondent”, which may be too narrow in 
the context of this paragraph.   Another term (for example, “survey”) might be added to 
the Glossary, to describe any means (e.g., questionnaire, diary, interview script) that is 
used to collect PRO data. 
 
Line 416-422 
“A scoring algorithm creates a single score from multiple items. Equally weighted scores 
for each item are appropriate only when the responses to the items are relatively 
uncorrelated. Otherwise, the assignment of equal weights will overweight correlated 
items and underweight independent items. Even when items are uncorrelated, assigning 
equal weights to each item may overweight certain items if the number of response 
options or the values associated with response options varies by item. The same 
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weighting concerns apply with added complexity when combining domain scores into a 
single overall score.” 
 
Suggested wording: 
“When a scoring algorithm is used to create a single score from multiple items, care 
should be taken to ensure that psychometric requirements for multi-item scoring are 
fulfilled. Item selection and weighting should ensure that the score adequately represent 
the concept of interest.  Equally weighted scores for each item is a widespread approach 
with considerable robustness, but care should be taken to document the validity of the 
approach or any other approach chosen. Inclusion of items that are conceptually too 
similar can lead scores to be overly influenced by a single domain. Care should also be 
taken when creating scores from items where the number of response options or the 
values associated with response options varies by item. The same weighting concerns 
apply with added complexity when combining domain scores into a single overall score.” 
 
Motivation: 
The intention of the original statement is probably to avoid the case when some domains 
are overly weighted in global indices by the inclusion of many similar items from the 
same domain. However, taken at face value the text is not correct according to 
psychometric research. Within item response theory, equal weighting of items is justified 
when items confirm to the so-called Rasch model. This is also true when items differ in 
their number of response choices (regardless of the sometimes heated debate on Rasch 
models versus other IRT models, all IRT experts would agree with the previous 
statements). An implication of this is that items can be combined without weighting when 
they have similar item discrimination and fulfill requirements of unidimensionality and 
local independence. Even if items are strongly correlated, an unweighted score is valid if 
these requirements are fulfilled. Further, a large body of research shows that equal 
weighting is robust to deviations from the requirement of equal item discrimination. 
Within classical psychometrics, equal weighting is justified when items have roughly 
equal variances and item-total correlations. However, items can also be highly correlated 
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in this case. This revision is important since the original wording would erroneously 
indicate that the scoring of highly valid and reliable PROs is wrong.   
 
Table 4 
“Have patients similar to those participating in the clinical trial confirmed the 
completeness and relevance of all items?”  
 
Suggested revision 
Does empirical evidence support that the measurement range and item content are 
relevant for the patient group participating in the clinical trial and that the items cover 
all aspects of the domain in question? 
  
Motivation: 
The original text seems to enforce particular approaches to assessing the completeness 
and relevance of all items (e.g., focus groups). While focus groups can be valuable in test 
development, the requirement that a similar group of patients should confirm the 
completeness and relevance of items every time a trial is launched seems counter-
productive. For example, for well-validated scales with a strong conceptual model (e.g., a 
scale of depression), should some items be dropped if one focus group questions their 
relevance? This could have dramatic consequences for the ability to compare results 
between studies and thus spoil the ability to interpret and generalize the results.    
 
Line 491 
“Test-retest reliability is the most important type of reliability” 
 
Suggested revision: 
“Test-retest reliability is the most generally applicable way of assessing reliability” 
 
Motivation: 
There are not different types of reliability but different ways of assessing reliability. The 
advantage of test-retest reliability is that it can be applied to single items measures.  
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Line 495-496 
“Internal consistency reliability, in the absence of test-retest reliability, does not 
generally constitute sufficient evidence of reliability for clinical trial purposes.” 
 
Suggested revision: 
“Internal consistency reliability for multi-item scale, in the absence of test-retest 
reliability, is sufficient evidence of reliability for clinical trial purposes only if the scoring 
assumptions have been carefully evaluated, and the domain in question does not exhibit 
large day-to-day variations.” 
 
Motivation: 
Available evidence shows that internal consistency reliability is a good estimator of 
reliability if the basic scoring assumptions are fulfilled. Domains with a considerable 
day-to-day variation will have less power in clinical trials (because of the larger variation 
in change scores) even if the instruments are reliable according to psychometric 
definitions of reliability. This issue pertains to the domain in question, not to the 
measurement instrument. 
 
Line 520 
When a concept is expected to change, the values for the PRO instrument measuring that 
concept should change. 
 
Suggested revision: 
When patient experience of a concept is expected to change, the values for the PRO 
instrument measuring that concept should change. 
 
Motivation: 
The concept being measured should not change; rather how the patient experiences the 
concept might change. 
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Line 547-548 
“An MID is usually specific to the population under study.” 
 
Suggested revision: 
An MID can depend on the score level and may differ between populations. Therefore, 
the use of an MID in a particular population with a particular score range should be 
justified. 
 
Motivation: 
While MID may vary by population, much evidence suggests that MID for generic 
measures are probably fairly population independent, once the possible variation in score 
range is taken into account. In the general discussion below, we present analyses to 
support this point. While this topic is under-researched, the original statement is too 
strong given current evidence.  
 
Line 586 
On the other hand, if the PRO instrument is to be used in an entirely new population of 
patients, a small randomized study to ascertain the measurement properties in the new 
population may minimize the risk that the instrument may not perform adequately in a 
phase 3 study. 
 
Suggested revision: 
On the other hand, if the PRO instrument is to be used in an entirely new population of 
patients, a sufficiently-powered study using a representative sample from the new 
population to ascertain the measurement properties may minimize the risk that the 
instrument may not perform adequately in a phase 3 study. 
 
Motivation: 
Most studies to determine the psychometric properties of an instrument are not 
randomized.  We propose that a “representative sample” from the new population be 
studied, rather than a random sample. It is prudent to encourage the use of sufficient 
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power in psychometric studies, including revalidation in a new sample.  The word 
“small” connotes a sample that may not be sufficient.  Feldt and Charter have many 
publications on the minimum sample sizes needed for sufficient stability of the 
psychometric estimates.  Otherwise, a point estimate of .85 for reliability could have a 
lower bound clearly in the unacceptable range.  Additionally, please see our General 
Comments (below) on a framework for validating the invariance of two populations on 
an instrument.   
 
Line 599 
A single domain from a multiple domain PRO is administered without the other domains. 
 
Suggested revision: 
Suggest deleting this statement. 
 
Motivation: 
It is not unusual for one or more scales from a multiple domain PRO to be used in a 
clinical trial.  For example, a single scale from the Sickness Impact Profile (SIP) might be 
included in a PRO instrument to measure a specific concept of interest, but the entire 
136-item SIP would not be included in the study.  If the measurement properties of a 
single scale from a multiple domain PRO have been shown to be adequate in the 
population of interest, it is not clear why an additional study of that scale alone is 
necessarily required.  
 
Line 612-613 
"Patients in the proposed trial have a disease, condition, or severity level that is different 
from that of the patient population used for instrument development and validation." 
 
Suggested revision: 
"Patients in the proposed trial have a disease or condition that is different from that of 
the patient population used for instrument development and validation.” 
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Motivation: 
Invariance literature has shown that severity of a condition does not have an impact on 
the measurement properties between the severity levels (the “less severe” and “more 
severe”).  Moreover, as long as each item has variance, floor and ceiling effects shouldn’t 
constrain the psychometric aspects between the severity levels.  Extreme differences 
between the severity levels (such as mentally impaired with an IQ of 40 compared to 
genius level with 140 IQ) create special circumstances, but such disparities rarely apply 
to medical conditions (wherein a ceiling of “normal” level is achieved).   
 
Line 752 
We suggest the following additions to the guidance: 
“Data quality should be evaluated before final data analysis is conducted and may also 
be monitored at regular intervals during the trial. Principles for data quality analysis 
should be specified in the protocol. Possible components of data quality analysis include: 
proportion of missing responses, proportion of invalid responses, inter-item and item-
total correlations, item discriminant validity and internal consistency reliability. 
 
Motivation: 
In our collaboration with companies conducting clinical trials, we have become aware of 
quality problems, even for studies submitted to the FDA and to leading clinical journals. 
Such problems include errors in scoring of data, which can totally invalidate the results 
but can easily be detected by simple tests. We therefore believe that the FDA could do 
the field a great service by insisting on better procedures for quality control in data 
collection and scoring. In our general discussion below, we present some simple ideas for 
monitoring data quality.   
 
Lines 1059-1060 
An HRQL measure captures, at a minimum, physical, psychological (including emotional 
and cognitive), and social functioning.    
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Suggested revision: 
An HRQL measure captures, at a minimum, physical, psychological and social 
functioning.    
 
Motivation: 
While there are some diseases in which cognitive functioning is expected to be impaired, 
many, if not most, people do not have noticeable decrements in cognitive functioning.  
Routine measurement of cognitive functioning in unimpaired populations adds 
unnecessary respondent burden and cost, and cognitive functioning has not been included 
in a number of widely-used generic measures, including the COOP charts, Duke Health 
Profile (17-item version), EQ-5D, FACT-G, and SF-36.  The issue of PRO measurement 
for patients who are cognitively impaired is addressed separately within the document, in 
Section E.2. 
 
Line 1067 
“Item – An individual question, statement or task that is evaluated by the patient to 
address a particular concept” 
 
Suggested revision: 
“Item – An individual question, statement or task (and its standardized response options) 
that is evaluated by the patient to address a particular concept” 
 
Motivation: 
Including response options in the definition of an item is helpful in emphasizing that 
response choices is an integral part of the item that needs to be carefully evaluated. 
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General discussion 
 
Comments on the use of Minimally Important Differences (MID) 
 
What is a Minimum Important Difference (MID)? 
Investigators, motivated by clinicians as well as by regulatory agencies, have found the 
need to differentiate between an important change in a target instrument and a trivial 
change, to define the smallest meaningful change in a score, what is often called the 
“minimum important difference” or MID.  A popular definition of MID is “the smallest 
difference in score in the domain of interest which patients perceive as beneficial and 
which would mandate, in the absence of troublesome side effects and excessive cost, a 
change in the patient’s (health care) management” 3. This definition seems linked to the 
experience and treatment of individual patients. The medical literature on MID 
recognizes that different considerations apply to the evaluation of mean group 
differences/score changes and to the evaluation of individual patient differences/score 
changes 4. Unfortunately, this has not been reflected in the definition of MID. We 
therefore think the separation offered in the FDA guidance is very useful and important: 
”… it is appropriate for a critical distinction to be made between the mean effect seen 
(and what effect might be considered important) and a change in an individual that 
would be considered important, perhaps leading to a definition of a responder.” (lines 
540-543):  The concept of MID will therefore in particular be relevant for decisions about 
sample size and study design, while the “responder definition” will be useful for 
treatment decisions in clinical practice (and to some extent for the interpretation of 
clinical trial results). However, both concepts should emphasize the value of the patient’s 
own perspective and link the patient’s view with that of clinicians; and both should be 
readily understood by clinicians and researchers4. 
 
Conceptual Frameworks for PRO Assessment and Deriving MID 
We propose that the conceptual frameworks discussed in the guidance should also be 
used in evaluating MID (see an example in Figure 1).  Such frameworks make important 
distinctions between domains of health and their operational definitions. Figure 1 
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portrays a specific-generic continuum 5 of PRO outcomes and links such outcomes to 
other variables useful for evaluating MID (also called anchor-based MID evaluation 4). 
As one moves from the left to the right, the measures change from being the most highly 
specific biological processes, to disease-specific or generic symptoms, to generic 
measures of functional impact, role function and use of health services.  
 
 
This conceptual framework also makes useful distinctions for evaluation of MID. PRO 
instruments that measure disease-specific impact on HRQOL may require population-
specific estimates that are derived from widely accepted clinical anchors. However, an 
important strength of generic instruments lies in their generalizability across specific 
sample populations, so that investigators can make meaningful comparisons between: (1) 
different studies of the same disease condition; (2) different conditions; and (3) patient 
groups and normative benchmarks without the condition. Such comparisons, by 
definition, require estimates of MID that are robust with respect to sample characteristics.  
 
A corollary issue is that a specific magnitude of change in a generic measure may have 
very different clinical implications depending on where a group is at baseline. For 
example, a change of 5 points on a physical functioning scale may have little or no real 
clinical implications if patients are close to normative levels at baseline. However, the 
same 5-point change may make the difference between being able to walk unassisted or 
Biological and 
Physiological 
Variables 
Symptom 
Status 
Functional 
Status 
General 
Health 
Perceptions 
Work 
Function 
Use of Health 
Services 
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Figure 1. PRO Conceptual Framework (adapted from 5) 
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requiring a wheelchair if patients are starting from a lower baseline value. Thus, when 
presenting MIDs, the score levels for which the MID apply should be specified.  
 
To illustrate this point, we present data from the Medical Outcomes Study, using the SF-
36 Vitality (VT) score as a predictor of 7-year mortality using four different regression 
(proportional hazards) models: (1) total sample (n=2,199); (2) total sample with control 
for disease group (n=2,199); (3) CHF patients only (n=156); and (4) Diabetes patients 
only (n=398). All analyses controlled for gender and age group. The comparison group is 
a VT score of 59, the mean of the General Population (VT score distribution and deaths 
shown in the bottom part of the graph). All analyses show a significant effect of the 
Vitality score, but also a significant quadratic effect. This means that score differences 
above the population mean of 59 are not predictive of subsequent mortality, while score 
differences below 59 are highly predictive of mortality. Further, the lower the score, the 
more important is a score difference of a certain magnitude (Bjorner et al, in preparation). 
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Once the score level is taken into consideration, we do not find large variations in MID 
by population. In preparation of this response, we analyzed public use data from 519,035 
participants in the Medicare Health Outcomes Survey (HOS). In 14 separate analyses, we 
performed anchor-based analyses for respondents reporting 14 different diseases to test 
whether the anchor-based MID would be stable across disease groups. The very large 
sample sizes in the HOS make this a very robust analysis. We evaluated MID for the SF-
36 Physical Component Summary (PCS) using logistic regression analyses with PCS as 
the independent variable and 2 year mortality as the dependent variable (the anchor). 
Based on logistic regression results, we calculated the PCS score difference associated 
with a 20% increase in mortality risk (please see table below). With one exception (CHF) 
the results show remarkable similarity across diseases, supporting an MID of 3 points for 
PCS if a 20% increase in mortality risk is regarded as significant. Analyses choosing a 
50% increase in mortality risk, as the threshold for minimal importance, show the same 
kind of stability across disease groups.   
 
PCS score differences as predictor of mortality at 2 year follow-up. Medicare 
Health Outcomes Survey (N=519,035) 
    
MID for PCS based on 
increase in mortality 
Disease group Total N (Deaths) Beta 
20% 
increase 
50% 
Increase 
Depression 37618 (5499) -0.0621 2.9 6.5 
AMI  48206 (7759) -0.0538 3.4 7.5 
Angina or CAD 72153 (10033) -0.0567 3.2 7.2 
Any Cancer  59477 (9781) -0.0567 3.2 7.2 
Arthritis hand or wrist 161596 (14437) -0.0567 3.2 7.2 
Arthritis hip or knee 185084 (16438) -0.0567 3.2 7.2 
CHF 31325 (8478) -0.0440 4.1 9.2 
COPD 59733 (9200) -0.0562 3.2 7.2 
Diabetes 81439 (10033) -0.0532 3.4 7.6 
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PCS score differences as predictor of mortality at 2 year follow-up. Medicare 
Health Outcomes Survey (N=519,035) 
    
MID for PCS based on 
increase in mortality 
Disease group Total N (Deaths) Beta 
20% 
increase 
50% 
Increase 
GI Problems 25364 (2688) -0.0532 3.4 7.6 
High BP 255713 (23675) -0.0564 3.2 7.2 
Other heart condition 97831 (12746) -0.0585 3.1 6.9 
Sciatica 109436 (9118) -0.0572 3.2 7.1 
Stroke 39049 (7453) -0.0509 3.6 8.0 
 
 
Results on MID from consensus groups of clinicians have differed between different 
populations, but also for different studies of the same population. The likely explanation 
is that the clinical consensus method is not very reliable and strongly depends on the 
information presented to the clinicians.  
 
One way of handling the dependence of MID on score level is to think of MID as a 
function rather than a single number. This is particularly important when deriving 
estimates of MID for generic PRO instruments, where one may use clinically-meaningful 
anchors that apply to a much broader population than those typically encountered when 
using disease-specific instruments. An MID function associated with a measure rests on 
the assumption that different populations may start at different baseline values on a 
measure, but that there exists a consistent relationship between the measure and the 
anchors that is robust to sample characteristics. Early phase and/or pilot studies can be 
used to estimate baseline values of a measure that one might expect in a clinical trial. 
These can be used as the basis for calculating MID from trial to trial, but the MID 
function itself does not change across populations. Determining if the relationship 
between a PRO measure and a chosen anchor is sensitive to potential covariates (type of 
disease condition, age, gender, etc) is a statistical issue that is well-handled using a 
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number of classical methods (e.g. regression, GLM) and should be checked in many 
populations. Limiting an MID estimation to a single clinical population designed to 
reflect the sample used in a drug trial creates interpretive difficulties. The 
inclusion/exclusion factors (e.g., medication washout periods) that shape a clinical trial 
population are designed for purposes of showing efficacy (not effectiveness), and 
therefore may lead to erroneous estimates that do not generalize to the typical primary 
care setting.   
 
Comments on Population-Specific Validation of PRO Instruments 
Population definition: 
It is currently difficult to understand the definition of a “population” within the guidance 
and what makes one group different from another.  Nevertheless, the guidance make clear 
that differences between the PRO development population and the intended population 
for a clinical trial require specific validation.  We believe it will prudent to provide 
clarification of what constitutes a substantial difference between populations.  
Differences between populations that have been empirically demonstrated in other 
research to be negligible on the outcome should not warrant a comprehensive revalidation 
effort.  For example, prior evidence that RA and Scleroderma patients respond similarly 
on the HAQ-DI, along with evidence that a highly related daily performance measure has 
been validated on RA patients, may be ample evidence to support use of the daily 
performance measure on Scleroderma patients.   
 
Invariance between samples: 
We were pleased to read the statistical recommendations for using PRO in studies, and 
the necessary psychometric evaluations for affirming a new instrument.  However, 
nothing was noted of the benefits of invariance testing to assure that instruments have 
similar psychometric properties in different populations 6;7.   Many studies assessing the 
similarity between two groups (including translated versions of an instrument) provide 
insufficient statistical accuracy.  We encourage the FDA to provide details of IRT and 
SEM-based invariance assessment for these various procedures.  A few excellent 
references are 8-11. 
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Comments on Data Quality Evaluation 
The first major objective of the analysis of PRO data in a clinical trial is to provide 
evidence to support the scaling and interpretation of scores from the PRO instrument.  
Many PRO instruments consist of multi-item scales that are scored using the method of 
summated ratings developed by Likert 12.  The method of summated rating scales has 
been widely adopted for the scoring of PRO measures because of its simplicity and 
success in yielding reliable scores.  For this reason we will focus on simple methods for 
evaluating summated rating scales, based on classical psychometrics. Sophisticated 
methods for evaluating measurement assumptions and data quality have also been 
developed using item response theory (within a health context see e.g.. 13;14). To compute 
a score using the summated rating method, scores assigned to responses are simply 
summed (in some situations after recoding items so that all items in a scale are in the 
same direction).  However, this simplicity is based on a number of assumptions that must 
be tested.  These tests determine the appropriateness of including an item in a particular 
scale and whether it is appropriate to simply sum item scores to estimate and interpret the 
scale score. Furthermore, these tests lend support to the validity of the measurement 
model developed for the PRO instrument and provide a means to evaluate whether errors 
were made in the coding, processing and scoring of the PRO scales.   
 
The first step in evaluating a summated ratings scale is to determine the extent of missing 
and out of range data.  A scale score cannot be estimated with confidence if there is a 
large amount of missing data.  A large amount of missing data for a particular item or 
items may indicate a problem with the wording of the item(s), with the wording of the 
response choices, or that respondents simply did not understand what was being asked 
with the question.  Item means and standard deviations should also be examined. Under 
traditional Likert scaling criteria, item means and standard deviations should be roughly 
equivalent within a scale.  However, depending on the purpose of measurement, the item 
means may be expected to be non-equivalent.  For example, in measuring a wide range of 
physical activities, from self care to strenuous activities, item means will generally vary, 
because most populations will differ in their underlying ability to perform such activities. 
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The multi-trait item-scale correlation matrix allows for a number of assumptions 
traditionally associated with Likert scaling to be examined including item internal 
consistency and item discriminant validity.  The first assumption is that an item should be 
substantially linearly related to the underlying concept being measured by the scale (test 
of item internal consistency).  This assumption is tested by examining the correlation 
between an item and its scale, after correcting for overlap 15. Item internal consistency is 
considered substantial and satisfactory if the item correlates 0.40 or more with its 
hypothesized scale (after correcting for overlap).  A less conservative standard of 0.30 
may be appropriate for evidence of item internal consistency for instruments in 
development.  Items should correlate positively with their hypothesized scale otherwise 
there may be an error in the coding or handling of the item (for example, item response 
values requiring reverse scoring). 
 
The second assumption, item discriminant validity, focuses on the integrity of 
hypothesized item groupings that are specified in the measurement model developed for a 
PRO instrument.  It is not sufficient enough to demonstrate that an item measures what it 
is supposed to measure (item internal consistency), it is also important to show that an 
item does not measure other concepts (scales).  Item discriminant validity is supported if 
the correlation between an item and its hypothesized scale is significantly higher than the 
correlations between that item and all other scales scored from the PRO instrument in a 
multi-trait item-scale correlation matrix. 
 
Another property of each scale that is investigated is reliability. While reliability is 
discussed in the Guidance in relation to instrument development and testing, we would 
add that internal consistency reliability may also be used as part of the evaluation of data 
quality.  
 
In summary, evidence to support the assumptions underlying the construction and scoring 
of PRO instruments is vital in documenting the quality of data in clinical studies and in 
supporting the interpretation of PRO scale scores.  These simple tests outlined above 
should be considered as part of the analysis plan designed for clinical studies and 
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implemented regularly at each time point in the study to ensure that the PRO data 
captured meets minimum psychometric standard for scoring, analysis and interpretation.  
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